First study in decade provides hope for patients suffering from primary biliary cirrhosis

March 31, 2011

Results from an international study presented today at the International Liver Congress have shown Obeticholic Acid (OCA) is a safe and effective treatment in patients suffering from Primary Biliary Cirrhosis (PBC) as demonstrated by substantial decreases in the levels of alkaline phosphatase (AP) enzyme in the blood, a key marker for PBC.

In this double blind parallel group study, 59 patients received 10 or 50mg of OCA or a placebo once a day for 12 weeks. After 12 weeks the 10mg group showed the greatest reduction in AP levels.

PBC is a chronic disease that slowly destroys some of the tubes (bile ducts) linking the liver to the gut. PBC predominantly affects females at a ratio of approximately nine women to every one man. Bile ducts carry bile to the gut but in patients with PBC, bile can no longer flow through effectively and instead builds up in the liver, damaging the and causing inflammation and scarring. Long-term damage over the years can result in cirrhosis and .

Daniele Prati, EAS's Scientific Committee Member and Press Committee Chairman commented: "It is extremely encouraging to see that OCA seems to be effective in patients from a variety of countries. This is the first treatment trial in many years for patients with PBC that has shown such promising results. Further studies are needed to evaluate the action of this therapy compared to existing therapies and in larger patient populations."

OCA, 6-ethyl chenodeoxycholic acid (CDCA) or INT-747, is a novel derivative of CDCA, the natural ligand for the farnesoid-X receptor, a bile acid receptor which is found in the .

More information: References


1. Kowdley V.K et al. An International Study Evaluating the Farnesopid X Receptor Agonist Obeticholic Acid as Monotherapy in PBC. Presented at The International Liver Congress 2011

2. Primary Biliary Cirrhosis, British Liver Trust. www.britishlivertrust.org.uk/h … liary-cirrhosis.aspx . Accessed March 2011

3. What is Primary Biliary Cirrhosis, PBC Foundation – support for life. www.pbcfoundation.org.uk/Information.htm . Accessed March 2011

Related Stories

Recommended for you

Alcohol consumption and metabolic factors act together to increase the risk of severe liver disease

November 22, 2017
A new study provides insights into the interaction between alcohol consumption and metabolic factors in predicting severe liver disease in the general population. The findings, which are published in Hepatology, indicate ...

Gastric acid suppressant lansoprazole may target tuberculosis

November 21, 2017
A cheap and widely used drug, used to treat conditions such as heartburn, gastritis and ulcers, could work against the bacteria that cause tuberculosis (TB), according to new research from UCL and the London School of Hygiene ...

Improving prediction accuracy of Crohn's disease based on repeated fecal sampling

November 21, 2017
Researchers at the University of California San Diego Center for Microbiome Innovation (CMI) have found that sampling the gut microbiome over time can provide insights that are not available with a single time point. The ...

Anti-malaria drug shows promise as Zika virus treatment

November 17, 2017
A new collaborative study led by researchers at Sanford Burnham Prebys Medical Discovery Institute (SBP) and UC San Diego School of Medicine has found that a medication used to prevent and treat malaria may also be effective ...

Decrease in sunshine, increase in Rickets

November 17, 2017
A University of Toronto student and professor have teamed up to discover that Britain's increasing cloudiness during the summer could be an important reason for the mysterious increase in Rickets among British children over ...

Scientists identify biomarkers that indicate likelihood of survival in infected patients

November 17, 2017
Scientists have identified a set of biomarkers that indicate which patients infected with the Ebola virus are most at risk of dying from the disease.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.